Sun Jie, He Sha, Rong Chao, Cen Hong, Tan Xiao-Hong
Department of Hematology/Oncology and Pediatric Oncology, Guangxi Medical University Affiliated Tumor Hospital, Nanning 530021， Guangxi Zhuang Autonomous Region, China.
Department of Hematology/Oncology and Pediatric Oncology, Guangxi Medical University Affiliated Tumor Hospital, Nanning 530021， Guangxi Zhuang Autonomous Region, China,E-mail:
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2022 Aug;30(4):1123-1128. doi: 10.19746/j.cnki.issn.1009-2137.2022.04.022.
To investigate the clinical characteristics, prognostic factors, and treatment outcomes of patients with limited-stage (Ann Arbor stage I or II) mantle cell lymphoma (MCL).
Examining consecutive the clinical characteristics, treatment outcomes and prognostic factors of 47 patients with stage I or II MCL diagnosed in Affiliated Tumor Hospital of Guangxi Medical University from January 2005 to June 2020 were analyzed retrospectively.
The median age of patients was 62(37-78) years old. 36 patients were male, accounting for 76.6% of the whole. Among these, 74.5% (n=35) of the diagnoses were estimated at II stage. According to Mantle cell lymphoma International Prognostic Index (MIPI), 28 patients (59.6%) were classified as low risk. Patients who received first-line treatment and could be evaluated received rituximab combined chemotherapy, chemotherapy alone, cytarabine containing chemotherapy or chemotherapy combined with local radiotherapy, the different first-line therapies did not affect the complete response (CR) rate of patients (P＞0.05). The median follow-up time was 81.5 months, the 5-year progression-free survival (PFS) was 37.4% and the 5-year overall survival (OS) rate was 80.6%. Multivariate analysis showed that Ki-67＞30% (P＜0.05) the independent adverse prognostic factor for PFS and OS.
Limited-stage MCL is rare. Patients with limited-stage MCL had a better outcome than those with III-IV stage MCL. Patients with limited-stage MCL whose Ki-67≤30% had better PFS and OS.
探讨局限期（Ann Arbor分期I期或II期）套细胞淋巴瘤（MCL）患者的临床特征、预后因素及治疗结果。
回顾性分析2005年1月至2020年6月在广西医科大学附属肿瘤医院确诊的47例I期或II期MCL患者的临床特征、治疗结果及预后因素。
患者中位年龄为62（37 - 78）岁。男性36例，占总体的76.6%。其中，74.5%（n = 35）的诊断为II期。根据套细胞淋巴瘤国际预后指数（MIPI），28例患者（59.6%）被归类为低风险。接受一线治疗且可评估的患者接受了利妥昔单抗联合化疗、单纯化疗、含阿糖胞苷的化疗或化疗联合局部放疗，不同的一线治疗方法不影响患者的完全缓解（CR）率（P＞0.05）。中位随访时间为81.5个月，5年无进展生存期（PFS）为37.4%，5年总生存期（OS）率为80.6%。多因素分析显示，Ki-67＞30%（P＜0.05）是PFS和OS的独立不良预后因素。
局限期MCL罕见。局限期MCL患者的预后优于III - IV期MCL患者。Ki-67≤30%的局限期MCL患者的PFS和OS较好。
